1,286 reports of this reaction
3.6% of all INDAPAMIDE reports
#1 most reported adverse reaction
HYPONATRAEMIA is the #1 most commonly reported adverse reaction for INDAPAMIDE, manufactured by ANI Pharmaceuticals, Inc.. There are 1,286 FDA adverse event reports linking INDAPAMIDE to HYPONATRAEMIA. This represents approximately 3.6% of all 35,549 adverse event reports for this drug.
Patients taking INDAPAMIDE who experience hyponatraemia should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
HYPONATRAEMIA is moderately reported among INDAPAMIDE users, representing a notable but not dominant share of adverse events.
In addition to hyponatraemia, the following adverse reactions have been reported for INDAPAMIDE:
The following drugs have also been linked to hyponatraemia in FDA adverse event reports:
HYPONATRAEMIA has been reported as an adverse event in 1,286 FDA reports for INDAPAMIDE. This does not prove causation, but indicates an association observed in post-market surveillance data.
HYPONATRAEMIA accounts for approximately 3.6% of all adverse event reports for INDAPAMIDE, making it one of the most commonly reported side effect.
If you experience hyponatraemia while taking INDAPAMIDE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.